UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparative Effectiveness of an mTOR‐Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple‐Negative Breast Cancer

The oncologist (Dayton, Ohio), 2018-11, Vol.23 (11), p.1300-1309

2018

Volltextzugriff (PDF)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

Therapeutic Advances in Medical Oncology, 2018-01, Vol.10, p.1758835918775697-1758835918775697

2018

Volltextzugriff (PDF)

Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer

Current oncology reports, 2023-07, Vol.25 (7), p.689-698

2023

Volltextzugriff (PDF)

Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer

JCO precision oncology, 2018 (2), p.1-15

2018

Volltextzugriff (PDF)

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

Journal of clinical oncology, 2023-09, Vol.41 (27), p.4433-4442

2023

Volltextzugriff (PDF)

Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

JCO precision oncology, 2024-03, Vol.8 (8), p.e2300124

2024

Volltextzugriff (PDF)

Clinical outcomes based on multigene profiling in metastatic breast cancer patients

Oncotarget, 2016-11, Vol.7 (47), p.76362-76373

2016

Volltextzugriff (PDF)

Sentinel node biopsy and regional recurrence following neoadjuvant chemotherapy in patients with isolated tumor cells: A rare event

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e12581-e12581

2022

Volltextzugriff (PDF)

Individualized treatment estimates to inform on personalized cancer care decisions for treatment selection and treatment management

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13571-e13571

2023

Volltextzugriff (PDF)

Interplay between B cell and GABA metabolism (GABAm) and association with immune evasion in breast carcinoma (BC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1097-1097

2022

Volltextzugriff (PDF)

Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS634-TPS634

2023

Volltextzugriff (PDF)

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS635-TPS635

2023

Volltextzugriff (PDF)

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS624-TPS624

2022

Volltextzugriff (PDF)

A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS617-TPS617

2022

Volltextzugriff (PDF)

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1127-TPS1127

2022

Volltextzugriff (PDF)

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2698-TPS2698

2022

Volltextzugriff (PDF)

Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2543-2543

2021

Volltextzugriff (PDF)

Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.588-588

2018

Volltextzugriff (PDF)

Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.561-561

2020

Volltextzugriff (PDF)

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS1110-TPS1110

2019

Volltextzugriff (PDF)

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1015-1015

2019

Volltextzugriff (PDF)

Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1033-1033

2018

Volltextzugriff (PDF)

Abstract 2273: Targeting the PI3KAKTmTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2273-2273

2016

Volltextzugriff (PDF)

Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2273-2273

2016

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)
Buchkapitel
(1)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Journal Of Clinical Oncology
(16)
Cancer Research
(4)
Jco Precision Oncology
(2)
Current Oncology Reports
(1)
Jama Oncology
(1)
Oncotarget
(1)
The Oncologist
(1)
The oncologist
(1)
Therapeutic Advances In Medical Oncology
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparative Effectiveness of an mTOR‐Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple‐Negative Breast Cancer

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer

Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab

Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

Clinical outcomes based on multigene profiling in metastatic breast cancer patients

Sentinel node biopsy and regional recurrence following neoadjuvant chemotherapy in patients with isolated tumor cells: A rare event

Individualized treatment estimates to inform on personalized cancer care decisions for treatment selection and treatment management

Interplay between B cell and GABA metabolism (GABAm) and association with immune evasion in breast carcinoma (BC)

Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial

A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design

Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data

Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes

Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC)

Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC)

Abstract 2273: Targeting the PI3KAKTmTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response

Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response

Suchergebnisse filtern